DME, also known as bisnormacromerine or as 3,4-dimethoxy-β-hydroxyphenethylamine (β-hydroxy-3,4-DMPEA), is a psychoactive drug of the phenethylamine and BOx families. DME Entry It is the β-hydroxy derivative of 3,4-dimethoxyphenethylamine (3,4-DMPEA or DMPEA), which is an analogue of mescaline (3,4,5-TMPEA or TMPEA).
Use and effects In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists DME's dose as greater than 115mg orally and its duration as unknown. At a dose of 115mg orally, its effects included faint nausea and possible alertness, but described as "substantially no effects".
Chemistry Synthesis The chemical synthesis of DME has been described.
Analogues Analogues of DME (β-hydroxy-3,4-DMPEA) include BOH (β-methoxy-MDPEA) and BOM (β-methoxymescaline; β-methoxy-3,4,5-TMPEA), among others. Other analogues include normacromerine (N-methyl-DME) and macromerine (N,N-dimethyl-DME).
History DME was first described in the scientific literature by Alexander Shulgin and colleagues in 1969. It was subsequently described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
Society and culture Legal status United Kingdom This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.
See also BOx (psychedelics) Substituted methoxyphenethylamine
References
External links DME - Isomer Design DME - PiHKAL - Erowid DME - PiHKAL - Isomer Design The Small & Handy BOX-Series Thread - Bluelight